For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Search Posts
Op-Eds
Rachel Carson’s legacy nothing to celebrate
Today is the centenary of Rachel Carson’s birth, which has been noted by many environmentalists who cherish her legacy. However, what has been little…
Blog
The Gotham Prize for Cancer
According to Reuters, medical researchers got together with hedge fund managers to institute the Gotham Prize for Cancer Research, a new private prize…
News Release
Another Revolution Needed For Biotech Medicines
Contact: Jody Clarke, 202.331.2252…
Blog
Rachel Was Wrong
Today we launch our campaign urging people to rethink the legacy of environmentalist icon Rachel Carson, with the site www.RachelWasWrong.com. Today she’s mostly remembered…
News Release
Rethinking the Rachel Carson Legacy
Washington, D.C., May 21, 2007—As environmentalists around the world prepare this week to celebrate the 100th birthday of author Rachel Carson, the Competitive Enterprise…
Blog
Tim Carney on Drugs
Our good friend Tim Carney writes in today’s Examiner about how Congress is pushing to expand the FDA’s authority over prescription drugs, and why…